IntelliPharmaCeutics International Receives a Hold from Aegis Capital

By Jason Carr

In a report released today, Difei Yang from Aegis Capital reiterated a Hold rating on IntelliPharmaCeutics International (NASDAQ: IPCI), with a price target of $2. The company’s shares closed yesterday at $2.12.

Yang noted:

“We believe the stay is more likely to last longer than 30 months, as is typical in most patent dispute cases.”

According to TipRanks.com, Yang is a 4-star analyst with an average return of 8.0% and a 45.1% success rate. Yang covers the Healthcare sector, focusing on stocks such as Protalix Biotherapeutics, Spectrum Pharmaceuticals, and Alder Biopharmaceuticals.

IntelliPharmaCeutics International has an analyst consensus of Moderate Buy, with a price target consensus of $2.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Intellipharmaceutics International, Inc. is a pharmaceutical company, which engages in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs. Its patented Hypermatrix technology is a multidimensional controlled-release drug delivery platform that can be applied to the development of existing and new pharmaceuticals in the areas of neurology, cardiovascular, gastrointestinal tract, diabetes and pain. The company was founded on October 22, 2009 and is headquartered in Toronto, Canada.